Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
Juan Manuel Carreño, Hala Alshammary, Gagandeep Singh, et al.
EBioMedicine (2021) Vol. 73, pp. 103626-103626
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Juan Manuel Carreño, Hala Alshammary, Johnstone Tcheou, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 682-688
Open Access | Times Cited: 466
Defining the risk of SARS-CoV-2 variants on immune protection
Marciela M. DeGrace, Elodie Ghedin, Matthew B. Frieman, et al.
Nature (2022) Vol. 605, Iss. 7911, pp. 640-652
Open Access | Times Cited: 152
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 118
An early warning system for emerging SARS-CoV-2 variants
Lorenzo Subissi, Anne von Gottberg, Lipi Thukral, et al.
Nature Medicine (2022) Vol. 28, Iss. 6, pp. 1110-1115
Open Access | Times Cited: 69
Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants
Ana S. González-Reiche, Hala Alshammary, Sarah Schaefer, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 57
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations
Juan Manuel Carreño, Gagandeep Singh, Johnstone Tcheou, et al.
Vaccine (2022) Vol. 40, Iss. 42, pp. 6114-6124
Open Access | Times Cited: 65
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Juan Manuel Carreño, Hala Alshammary, Johnstone Tcheou, et al.
Nature (2021)
Open Access | Times Cited: 56
SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium
Mart M. Lamers, Anna Z. Mykytyn, Tim I. Breugem, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 47
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial
Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
EClinicalMedicine (2022) Vol. 45, pp. 101323-101323
Open Access | Times Cited: 44
The past, current and future epidemiological dynamic of SARS-CoV-2
François Balloux, Cedric C.S. Tan, Leo Swadling, et al.
Oxford Open Immunology (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 37
Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants
Amin Addetia, Luca Piccoli, James Brett Case, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 30
Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients
Joann Diray‐Arce, Slim Fourati, Naresh Doni Jayavelu, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 6, pp. 101079-101079
Open Access | Times Cited: 26
What makes SARS‐CoV‐2 unique? Focusing on the spike protein
Jingbo Qian, Shi-Chang Zhang, Fang Wang, et al.
Cell Biology International (2024) Vol. 48, Iss. 4, pp. 404-430
Open Access | Times Cited: 12
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19
Roberto Lozano‐Rodríguez, Jaime Valentín‐Quiroga, José Avendaño‐Ortiz, et al.
Cell Reports (2021) Vol. 38, Iss. 2, pp. 110235-110235
Open Access | Times Cited: 46
Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial
Zoltán Bánki, José Mateus, Annika Rössler, et al.
EBioMedicine (2022) Vol. 80, pp. 104073-104073
Open Access | Times Cited: 36
PARIS and SPARTA: Finding the Achilles’ Heel of SARS-CoV-2
Viviana Simon, Vamsi Kota, Ryan F. Bloomquist, et al.
mSphere (2022) Vol. 7, Iss. 3
Open Access | Times Cited: 30
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam
Anh Duc Dang, Vũ Đình Thiểm, Ha Hai Vu, et al.
Vaccine (2022) Vol. 40, Iss. 26, pp. 3621-3632
Open Access | Times Cited: 29
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
Barbara Mühlemann, Samuel Wilks, Lauren Baracco, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 747
Closed Access | Times Cited: 5
XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies
Juan Manuel Carreño, Brian Lerman, Gagandeep Singh, et al.
mBio (2025)
Open Access
Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals
Jéromine Klingler, Gregory S. Lambert, Vincenza Itri, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 35
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
Edwards Pradenas, Benjamin Trinité, Víctor Urrea, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 2, pp. 100523-100523
Open Access | Times Cited: 23
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination
Juan Manuel Carreño, Ariel Raskin, Gagandeep Singh, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 683
Open Access | Times Cited: 14
SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020–2023
Juan Manuel Carreño, Abram L. Wagner, Brian Monahan, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice
Shuo Song, Bing Zhou, Lin Cheng, et al.
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 21
Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
Irene González‐Domínguez, José Luis Martínez, Stefan Slamanig, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top